ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

TARS vs BEAM // EV/EBITDA & P/E VALUATION

Tarsus Pharmaceuticals Inc. (NASDAQ) VS. Beam Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: TARS 8 — BEAM 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TARS VS. BEAM) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC TARS BEAM SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -24.10% -32.10% +8.00 TARS /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -0.61% -12.09% +11.48 TARS /fcf-yield <GO>
Operating Margin -15.70% -60.00% +44.30 TARS /operating-margins <GO>
Net Profit Margin -14.60% -57.20% +42.60 TARS /net-margins <GO>
Revenue Growth (YoY) 146.70% 120.00% +26.70 TARS /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 10.19 6.00 +4.19 TARS /balance-sheet <GO>
Piotroski F-Score Quality 5/9 3/9 +2.00 TARS /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 55.1 57.7 -2.58 BEAM /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $3.66B $2.98B $679.5M TARS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR TARS REV BEAM REV TARS GROSS % BEAM GROSS % TARS FCF BEAM FCF
FY 2025 $451.4M $139.7M — — -$22.3M -$360.0M
FY 2024 $183.0M $63.5M — — -$84.6M -$356.2M
FY 2023 $17.4M $377.7M — — -$117.5M -$149.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TARS // BETA —
BEAM // BETA —